Alchemia Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
11,066.00
5,138.00
1,873.90
1,920.90
1,620.30
Total Accounts Receivable
8,392.00
8,074.00
646.90
84.80
8.70
Other Current Assets
942.00
605.00
417.40
72.00
75.90
Total Current Assets
20,400.00
13,817.00
2,938.20
2,077.60
1,704.90
Net Property, Plant & Equipment
307.00
162.00
-
-
-
Intangible Assets
13,404.00
-
-
-
-
Other Assets
-
-
-
205.20
178.30
Total Assets
34,131.00
14,632.00
2,938.20
2,282.80
1,883.20
Accounts Payable
1,633.00
309.00
171.50
64.00
29.90
Income Tax Payable
135.00
62.00
-
-
-
Other Current Liabilities
2,634.00
2,751.00
30.00
22.40
29.60
Total Current Liabilities
4,402.00
3,122.00
201.50
86.40
59.50
Provision for Risks & Charges
374.00
-
-
-
-
Deferred Taxes
2,285.00
652.00
-
-
-
Total Liabilities
7,081.00
3,123.00
201.50
86.40
59.50
Common Equity (Total)
27,050.00
11,509.00
2,736.70
2,196.40
1,823.70
Total Shareholders' Equity
27,050.00
11,509.00
2,736.70
2,196.40
1,823.70
Total Equity
27,050.00
11,509.00
2,736.70
2,196.40
1,823.70
Liabilities & Shareholders' Equity
34,131.00
14,632.00
2,938.20
2,282.80
1,883.20

About Alchemia

View Profile
Address
100 Albert Road
Melbourne Victoria (VIC) 3205
Australia
Employees -
Website http://www.alchemia.net.au
Updated 07/08/2019
Alchemia Ltd. is a biotechnology company, which engages in developing new human therapeutics based on its proprietary drug discovery, drug targeting and synthesis technologies. It involves in the research and development of new human pharmaceuticals. The company also engages in the commercialization and improvements of its generic fondaparinux product.